As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging

JAMA. 2023 Dec 12;330(22):2140-2142. doi: 10.1001/jama.2023.16620.
No abstract available

Plain language summary

This Medical News article discusses Wegovy, Ozempic, and other GLP-1 receptor agonists used for weight management and type 2 diabetes.

Publication types

  • News

MeSH terms

  • Anti-Obesity Agents* / adverse effects
  • Anti-Obesity Agents* / therapeutic use
  • Humans
  • Obesity* / drug therapy

Substances

  • semaglutide
  • Anti-Obesity Agents